{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T23:51:51Z","timestamp":1792281111051,"version":"4.4.0"},"reference-count":98,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100021171","name":"Guangdong Basic and Applied Basic Research Foundation","doi-asserted-by":"crossref","award":["2022A1515140138, 2024A1515140131"],"award-info":[{"award-number":["2022A1515140138, 2024A1515140131"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003785","name":"Medical Scientific Research Foundation of Guangdong Province of China","doi-asserted-by":"crossref","award":["A2024138, B2025580"],"award-info":[{"award-number":["A2024138, B2025580"]}],"id":[{"id":"10.13039\/501100003785","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Guangdong Provincial Hospital Pharmacy Research Fund","award":["2025A01002"],"award-info":[{"award-number":["2025A01002"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Diabetol"],"DOI":"10.1007\/s00592-026-02697-2","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T09:59:27Z","timestamp":1778234367000},"page":"1247-1263","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The effect of GLP-1 receptor agonists on osteoarthritis risk in individuals with type 2 diabetes mellitus: a systematic review and network meta-analysis of randomized controlled trials"],"prefix":"10.1007","volume":"63","author":[{"given":"Limin","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiyang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongxiang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7109-402X","authenticated-orcid":false,"given":"Baocheng","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,8]]},"reference":[{"issue":"9","key":"2697_CR1","doi-asserted-by":"publisher","first-page":"246","DOI":"10.15585\/mmwr.mm6609e1","volume":"66","author":"KE Barbour","year":"2017","unstructured":"Barbour KE, Helmick CG, Boring M et al (2017) Vital Signs: Prevalence of doctor-diagnosed arthritis and arthritis-attributable activity limitation - United States, 2013\u20132015. MMWR Morb Mortal Wkly Rep 66(9):246\u2013253. https:\/\/doi.org\/10.15585\/mmwr.mm6609e1","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"8","key":"2697_CR2","doi-asserted-by":"publisher","first-page":"818","DOI":"10.3390\/cells8080818","volume":"8","author":"D Tateiwa","year":"2019","unstructured":"Tateiwa D, Yoshikawa H, Kaito T (2019) Cartilage and bone destruction in arthritis: pathogenesis and treatment strategy: a literature review. Cells 8(8):818. https:\/\/doi.org\/10.3390\/cells8080818","journal-title":"Cells"},{"issue":"1","key":"2697_CR3","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/s41413-023-00301-9","volume":"11","author":"G Wei","year":"2023","unstructured":"Wei G, Lu K, Umar M et al (2023) Risk of metabolic abnormalities in osteoarthritis: a new perspective to understand its pathological mechanisms. Bone Res 11(1):63. https:\/\/doi.org\/10.1038\/s41413-023-00301-9","journal-title":"BoneRes"},{"issue":"10365","key":"2697_CR4","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1016\/S0140-6736(22)01655-5","volume":"400","author":"E Ahmad","year":"2022","unstructured":"Ahmad E, Lim S, Lamptey R et al (2022) Type 2 diabetes. Lancet 400(10365):1803\u20131820. https:\/\/doi.org\/10.1016\/S0140-6736(22)01655-5","journal-title":"Lancet"},{"key":"2697_CR5","doi-asserted-by":"publisher","first-page":"109119","DOI":"10.1016\/j.diabres.2021.109119","volume":"183","author":"H Sun","year":"2022","unstructured":"Sun H, Saeedi P, Karuranga S et al (2022) IDF diabetes atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract 183:109119. https:\/\/doi.org\/10.1016\/j.diabres.2021.109119","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"2697_CR6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.semarthrit.2019.01.005","volume":"49","author":"N Veronese","year":"2019","unstructured":"Veronese N, Cooper C, Reginster JY et al (2019) Type 2 diabetes mellitus and osteoarthritis. Semin Arthritis Rheum 49(1):9\u201319. https:\/\/doi.org\/10.1016\/j.semarthrit.2019.01.005","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"2697_CR7","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/phar.70005","volume":"45","author":"M Ryan","year":"2025","unstructured":"Ryan M, Megyeri S, Nuffer W et al (2025) The potential role of GLP-1 receptor agonists in osteoarthritis. Pharmacotherapy 45(3):177\u2013186. https:\/\/doi.org\/10.1002\/phar.70005","journal-title":"Pharmacotherapy"},{"issue":"2","key":"2697_CR8","doi-asserted-by":"publisher","first-page":"e70128","DOI":"10.1002\/msc.70128","volume":"23","author":"HF Hart","year":"2025","unstructured":"Hart HF, White DK, Reichert SM et al (2025) Associations of physical activity, sedentary behaviour, pain, function and quality of life with diabetes and knee osteoarthritis: data from the osteoarthritis initiative. Musculoskelet Care 23(2):e70128. https:\/\/doi.org\/10.1002\/msc.70128","journal-title":"Musculoskelet Care"},{"issue":"8","key":"2697_CR9","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.3390\/biomedicines12081630","volume":"12","author":"I Halabitska","year":"2024","unstructured":"Halabitska I, Babinets L, Oksenych V et al (2024) Diabetes and osteoarthritis: exploring the interactions and therapeutic implications of insulin, metformin, and GLP-1-based interventions. Biomedicines 12(8):1630. https:\/\/doi.org\/10.3390\/biomedicines12081630","journal-title":"Biomedicines"},{"issue":"6","key":"2697_CR10","doi-asserted-by":"publisher","first-page":"e41243","DOI":"10.1097\/MD.0000000000041243","volume":"104","author":"CP Lin","year":"2025","unstructured":"Lin CP, Chung CH, Lu CH et al (2025) Glucagon-like peptide-1 receptor agonists therapy to attenuate the risk of knee osteoarthritis and total knee replacement in type 2 diabetes mellitus: a nation-wide population-based cohort study. Med (Baltim) 104(6):e41243. https:\/\/doi.org\/10.1097\/MD.0000000000041243","journal-title":"Med (Baltim)"},{"issue":"10","key":"2697_CR11","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1016\/j.arth.2024.06.008","volume":"39","author":"MS Lavu","year":"2024","unstructured":"Lavu MS, Porto JR, Hecht CJ 2 et al (2024) The five-year incidence of progression to osteoarthritis and total joint arthroplasty in patients prescribed glucagon-like peptide 1 receptor agonists. J Arthroplasty 39(10):2433\u20132439e1. https:\/\/doi.org\/10.1016\/j.arth.2024.06.008","journal-title":"J Arthroplasty"},{"key":"2697_CR12","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"2697_CR13","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898","journal-title":"BMJ"},{"issue":"3","key":"2697_CR14","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1111\/biom.12817","volume":"74","author":"L Lin","year":"2018","unstructured":"Lin L, Chu H (2018) Quantifying publication bias in meta-analysis. Biometrics 74(3):785\u2013794. https:\/\/doi.org\/10.1111\/biom.12817","journal-title":"Biometrics"},{"issue":"2","key":"2697_CR15","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1002\/jrsm.12","volume":"1","author":"M Borenstein","year":"2010","unstructured":"Borenstein M, Hedges LV, Higgins JP et al (2010) A basic introduction to fixed-effect and random-effects models for meta-analysis. Res Synth Methods 1(2):97\u2013111. https:\/\/doi.org\/10.1002\/jrsm.12","journal-title":"Res Synth Methods"},{"issue":"7414","key":"2697_CR16","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ et al (2003) Measuring inconsistency in meta-analyses. BMJ 327(7414):557\u2013560. https:\/\/doi.org\/10.1136\/bmj.327.7414.557","journal-title":"BMJ"},{"key":"2697_CR17","doi-asserted-by":"publisher","first-page":"e2017047","DOI":"10.4178\/epih.e2017047","volume":"39","author":"S Shim","year":"2017","unstructured":"Shim S, Yoon BH, Shin IS et al (2017) Network meta-analysis: application and practice using Stata. Epidemiol Health 39:e2017047. https:\/\/doi.org\/10.4178\/epih.e2017047","journal-title":"Epidemiol Health"},{"key":"2697_CR18","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jclinepi.2023.02.016","volume":"157","author":"CR Nevill","year":"2023","unstructured":"Nevill CR, Cooper NJ, Sutton AJ (2023) A multifaceted graphical display, including treatment ranking, was developed to aid interpretation of network meta-analysis. J Clin Epidemiol 157:83\u201391. https:\/\/doi.org\/10.1016\/j.jclinepi.2023.02.016","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"2697_CR19","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.jclinepi.2007.03.013","volume":"61","author":"J Wetterslev","year":"2008","unstructured":"Wetterslev J, Thorlund K, Brok J, Gluud C (2008) Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. J Clin Epidemiol 61(1):64\u201375. https:\/\/doi.org\/10.1016\/j.jclinepi.2007.03.013","journal-title":"J ClinEpidemiol"},{"issue":"2","key":"2697_CR20","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s00125-006-0510-2","volume":"50","author":"MA Nauck","year":"2007","unstructured":"Nauck MA, Duran S, Kim D et al (2007) A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 50(2):259\u2013267. https:\/\/doi.org\/10.1007\/s00125-006-0510-2","journal-title":"Diabetologia"},{"issue":"1","key":"2697_CR21","doi-asserted-by":"publisher","first-page":"84","DOI":"10.2337\/dc08-1355","volume":"32","author":"M Nauck","year":"2009","unstructured":"Nauck M, Frid A, Hermansen K et al (2009) Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 32(1):84\u201390. https:\/\/doi.org\/10.2337\/dc08-1355","journal-title":"Diabetes Care"},{"issue":"4","key":"2697_CR22","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1111\/j.1463-1326.2009.01194.x","volume":"12","author":"K Kaku","year":"2010","unstructured":"Kaku K, Rasmussen MF, Clauson P et al (2010) Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes. Diabetes Obes Metab 12(4):341\u2013347. https:\/\/doi.org\/10.1111\/j.1463-1326.2009.01194.x","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"2697_CR23","doi-asserted-by":"publisher","first-page":"103","DOI":"10.7326\/0003-4819-154-2-201101180-00300","volume":"154","author":"JB Buse","year":"2011","unstructured":"Buse JB, Bergenstal RM, Glass LC et al (2011) Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med 154(2):103\u2013112. https:\/\/doi.org\/10.7326\/0003-4819-154-2-201101180-00300","journal-title":"Ann Intern Med"},{"issue":"4","key":"2697_CR24","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1111\/j.1742-1241.2011.02656.x","volume":"65","author":"R Pratley","year":"2011","unstructured":"Pratley R, Nauck M, Bailey T et al (2011) One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial. Int J Clin Pract 65(4):397\u2013407. https:\/\/doi.org\/10.1111\/j.1742-1241.2011.02656.x","journal-title":"Int J Clin Pract"},{"issue":"9833","key":"2697_CR25","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1016\/S0140-6736(12)60479-6","volume":"379","author":"B Gallwitz","year":"2012","unstructured":"Gallwitz B, Guzman J, Dotta F et al (2012) Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial. Lancet 379(9833):2270\u20132278. https:\/\/doi.org\/10.1016\/S0140-6736(12)60479-6","journal-title":"Lancet"},{"issue":"11","key":"2697_CR26","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1111\/dom.12121","volume":"15","author":"M Pinget","year":"2013","unstructured":"Pinget M, Goldenberg R, Niemoeller E et al (2013) Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P). Diabetes Obes Metab 15(11):1000\u20131007. https:\/\/doi.org\/10.1111\/dom.12121","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"2697_CR27","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.2337\/dc12-2006","volume":"36","author":"B Ahr\u00e9n","year":"2013","unstructured":"Ahr\u00e9n B, Leguizamo Dimas A, Miossec P et al (2013) Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M). Diabetes Care 36(9):2543\u20132550. https:\/\/doi.org\/10.2337\/dc12-2006","journal-title":"Diabetes Care"},{"issue":"7","key":"2697_CR28","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1007\/s00125-013-2905-1","volume":"56","author":"B Charbonnel","year":"2013","unstructured":"Charbonnel B, Steinberg H, Eymard E et al (2013) Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical trial. Diabetologia 56(7):1503\u20131511. https:\/\/doi.org\/10.1007\/s00125-013-2905-1","journal-title":"Diabetologia"},{"issue":"9","key":"2697_CR29","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.2337\/dc12-2462","volume":"36","author":"MC Riddle","year":"2013","unstructured":"Riddle MC, Forst T, Aronson R et al (2013) Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1). Diabetes Care 36(9):2497\u20132503. https:\/\/doi.org\/10.2337\/dc12-2462","journal-title":"Diabetes Care"},{"issue":"4","key":"2697_CR30","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/S2213-8587(13)70214-6","volume":"2","author":"RE Pratley","year":"2014","unstructured":"Pratley RE, Nauck MA, Barnett AH et al (2014) Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study. Lancet Diabetes Endocrinol 2(4):289\u2013297. https:\/\/doi.org\/10.1016\/S2213-8587(13)70214-6","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10","key":"2697_CR31","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.2337\/dc14-0876","volume":"37","author":"M Diamant","year":"2014","unstructured":"Diamant M, Nauck MA, Shaginian R et al (2014) Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes. Diabetes Care 37(10):2763\u20132773. https:\/\/doi.org\/10.2337\/dc14-0876","journal-title":"Diabetes Care"},{"issue":"8","key":"2697_CR32","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.2337\/dc13-2759","volume":"37","author":"G Umpierrez","year":"2014","unstructured":"Umpierrez G, Tof\u00e9 Povedano S, P\u00e9rez Manghi F et al (2014) Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care 37(8):2168\u20132176. https:\/\/doi.org\/10.2337\/dc13-2759","journal-title":"DiabetesCare"},{"issue":"12","key":"2697_CR33","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1007\/s00125-014-3360-3","volume":"57","author":"PN Weissman","year":"2014","unstructured":"Weissman PN, Carr MC, Ye J et al (2014) HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea. Diabetologia 57(12):2475\u20132484. https:\/\/doi.org\/10.1007\/s00125-014-3360-3","journal-title":"Diabetologia"},{"issue":"8","key":"2697_CR34","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.2337\/dc14-0001","volume":"37","author":"J Rosenstock","year":"2014","unstructured":"Rosenstock J, Fonseca VA, Gross JL et al (2014) Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro. Diabetes Care 37(8):2317\u20132325. https:\/\/doi.org\/10.2337\/dc14-0001","journal-title":"Diabetes Care"},{"issue":"11","key":"2697_CR35","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/S2213-8587(14)70174-3","volume":"2","author":"SC Gough","year":"2014","unstructured":"Gough SC, Bode B, Woo V et al (2014) Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes. Lancet Diabetes Endocrinol 2(11):885\u2013893. https:\/\/doi.org\/10.1016\/S2213-8587(14)70174-3","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"2697_CR36","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1111\/dme.12328","volume":"31","author":"GB Bolli","year":"2014","unstructured":"Bolli GB, Munteanu M, Dotsenko S et al (2014) Efficacy and safety of lixisenatide once daily vs. placebo in people with Type 2 diabetes insufficiently controlled on metformin (GetGoal-F1). Diabet Med 31(2):176\u2013184. https:\/\/doi.org\/10.1111\/dme.12328","journal-title":"Diabet Med"},{"issue":"9","key":"2697_CR37","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1111\/dom.12479","volume":"17","author":"RS Weinstock","year":"2015","unstructured":"Weinstock RS, Guerci B, Umpierrez G et al (2015) Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2 years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study. Diabetes Obes Metab 17(9):849\u2013858. https:\/\/doi.org\/10.1111\/dom.12479","journal-title":"Diabetes Obes Metab"},{"issue":"9982","key":"2697_CR38","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1016\/S0140-6736(15)60936-9","volume":"385","author":"L Blonde","year":"2015","unstructured":"Blonde L, Jendle J, Gross J et al (2015) Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study. Lancet 385(9982):2057\u20132066. https:\/\/doi.org\/10.1016\/S0140-6736(15)60936-9","journal-title":"Lancet"},{"issue":"12","key":"2697_CR39","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.2337\/dc14-1625","volume":"38","author":"F Giorgino","year":"2015","unstructured":"Giorgino F, Benroubi M, Sun JH et al (2015) Efficacy and Safety of once-weekly dulaglutide versus insulin glargine in patients with type 2 diabetes on metformin and glimepiride (AWARD-2). Diabetes Care 38(12):2241\u20132249. https:\/\/doi.org\/10.2337\/dc14-1625","journal-title":"Diabetes Care"},{"issue":"7","key":"2697_CR40","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1001\/jama.2015.9676","volume":"314","author":"MJ Davies","year":"2015","unstructured":"Davies MJ, Bergenstal R, Bode B et al (2015) Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial. JAMA 314(7):687\u2013699. https:\/\/doi.org\/10.1001\/jama.2015.9676","journal-title":"JAMA"},{"issue":"23","key":"2697_CR41","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","volume":"373","author":"MA Pfeffer","year":"2015","unstructured":"Pfeffer MA, Claggett B, Diaz R et al (2015) Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 373(23):2247\u20132257. https:\/\/doi.org\/10.1056\/NEJMoa1509225","journal-title":"N Engl J Med"},{"issue":"19","key":"2697_CR42","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A et al (2016) Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375(19):1834\u20131844. https:\/\/doi.org\/10.1056\/NEJMoa1607141","journal-title":"N Engl J Med"},{"issue":"4","key":"2697_CR43","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K et al (2016) Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375(4):311\u2013322. https:\/\/doi.org\/10.1056\/NEJMoa1603827","journal-title":"N Engl J Med"},{"issue":"11","key":"2697_CR44","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.2337\/dc16-1495","volume":"39","author":"VR Aroda","year":"2016","unstructured":"Aroda VR, Rosenstock J, Wysham C et al (2016) Efficacy and safety of lixilan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide in type 2 diabetes inadequately controlled on basal insulin and metformin: the lixiLan-L randomized trial. Diabetes Care 39(11):1972\u20131980. https:\/\/doi.org\/10.2337\/dc16-1495","journal-title":"Diabetes Care"},{"issue":"4","key":"2697_CR45","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1111\/dom.12624","volume":"18","author":"M Yu","year":"2016","unstructured":"Yu M, Van Brunt K, Varnado OJ et al (2016) Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: data from the AWARD phase III clinical trial programme. Diabetes Obes Metab 18(4):419\u2013424. https:\/\/doi.org\/10.1111\/dom.12624","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"2697_CR46","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.2337\/dc16-0046","volume":"39","author":"J Rosenstock","year":"2016","unstructured":"Rosenstock J, Diamant M, Aroda VR et al (2016) Efficacy and safety of lixiLan, a titratable fixed-ratio combination of lixisenatide and insulin glargine, versus insulin glargine in type 2 diabetes inadequately controlled on metformin monotherapy: the lixiLan proof-of-concept randomized trial. Diabetes Care 39(9):1579\u20131586. https:\/\/doi.org\/10.2337\/dc16-0046","journal-title":"Diabetes Care"},{"issue":"11","key":"2697_CR47","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.2337\/dc16-0917","volume":"39","author":"J Rosenstock","year":"2016","unstructured":"Rosenstock J, Aronson R, Grunberger G et al (2016) Benefits of lixiLan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide, versus insulin glargine and lixisenatide monocomponents in type 2 diabetes inadequately controlled on oral agents: the lixiLan-O randomized trial. Diabetes Care 39(11):2026\u20132035. https:\/\/doi.org\/10.2337\/dc16-0917","journal-title":"Diabetes Care"},{"issue":"2","key":"2697_CR48","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1007\/s00125-015-3795-1","volume":"59","author":"MA Nauck","year":"2016","unstructured":"Nauck MA, Stewart MW, Perkins C et al (2016) Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetologia 59(2):266\u2013274. https:\/\/doi.org\/10.1007\/s00125-015-3795-1","journal-title":"Diabetologia"},{"issue":"1","key":"2697_CR49","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/jdi.12367","volume":"7","author":"K Kaku","year":"2016","unstructured":"Kaku K, Kiyosue A, Ono Y et al (2016) Liraglutide is effective and well tolerated in combination with an oral antidiabetic drug in Japanese patients with type 2 diabetes: a randomized, 52-week, open-label, parallel-group trial. J Diabetes Investig 7(1):76\u201384. https:\/\/doi.org\/10.1111\/jdi.12367","journal-title":"J Diabetes Investig"},{"key":"2697_CR50","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.diabres.2017.06.013","volume":"131","author":"PD Home","year":"2017","unstructured":"Home PD, Ahr\u00e9n B, Reusch JEB et al (2017) Three-year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: long-term efficacy with or without rescue therapy. Diabetes Res Clin Pract 131:49\u201360. https:\/\/doi.org\/10.1016\/j.diabres.2017.06.013","journal-title":"Diabetes Res Clin Pract"},{"issue":"15","key":"2697_CR51","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1001\/jama.2017.14752","volume":"318","author":"M Davies","year":"2017","unstructured":"Davies M, Pieber TR, Hartoft-Nielsen ML et al (2017) Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes: a randomized clinical trial. JAMA 318(15):1460\u20131470. https:\/\/doi.org\/10.1001\/jama.2017.14752","journal-title":"JAMA"},{"issue":"1","key":"2697_CR52","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s12955-017-0696-7","volume":"15","author":"S Suzuki","year":"2017","unstructured":"Suzuki S, Oura T, Takeuchi M et al (2017)Evaluation of the impact of once weekly dulaglutide on patient-reported outcomes in Japanese patients with type 2 diabetes: comparisons with liraglutide, insulin glargine, and placebo in two randomized studies. Health Qual Life Outcomes 15(1):123. https:\/\/doi.org\/10.1186\/s12955-017-0696-7","journal-title":"Health Qual Life Outcomes"},{"issue":"5","key":"2697_CR53","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/S2213-8587(17)30085-2","volume":"5","author":"VR Aroda","year":"2017","unstructured":"Aroda VR, Bain SC, Cariou B et al (2017) Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. Lancet Diabetes Endocrinol 5(5):355\u2013366. https:\/\/doi.org\/10.1016\/S2213-8587(17)30085-2","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"2697_CR54","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1016\/j.clinthera.2017.10.002","volume":"39","author":"M Yu","year":"2017","unstructured":"Yu M, Brunt KV, Milicevic Z et al (2017) Patient-reported Outcomes in patients with type 2 diabetes treated with dulaglutide added to titrated insulin glargine (AWARD-9). Clin Ther 39(11):2284\u20132295. https:\/\/doi.org\/10.1016\/j.clinthera.2017.10.002","journal-title":"Clin Ther"},{"issue":"10157","key":"2697_CR55","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","volume":"392","author":"AF Hernandez","year":"2018","unstructured":"Hernandez AF, Green JB, Janmohamed S et al (2018) Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet 392(10157):1519\u20131529. https:\/\/doi.org\/10.1016\/S0140-6736(18)32261-X","journal-title":"Lancet"},{"issue":"8","key":"2697_CR56","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/S2213-8587(18)30104-9","volume":"6","author":"KR Tuttle","year":"2018","unstructured":"Tuttle KR, Lakshmanan MC, Rayner B et al (2018) Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. Lancet Diabetes Endocrinol 6(8):605\u2013617. https:\/\/doi.org\/10.1016\/S2213-8587(18)30104-9","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"2697_CR57","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.2337\/dc17-1114","volume":"41","author":"LK Billings","year":"2018","unstructured":"Billings LK, Doshi A, Gouet D et al (2018) Efficacy and safety of IDegLira versus basal-bolus insulin therapy in patients with type 2 diabetes uncontrolled on metformin and basal insulin: the DUAL VII randomized clinical trial. Diabetes Care 41(5):1009\u20131016. https:\/\/doi.org\/10.2337\/dc17-1114","journal-title":"Diabetes Care"},{"issue":"4","key":"2697_CR58","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1007\/s13300-019-0646-y","volume":"10","author":"Y Li","year":"2019","unstructured":"Li Y, Li L, De Peng Y et al (2019) Efficacy and safety of dulaglutide versus insulin glargine in Chinese T2DM patients: a subgroup analysis of a randomized trial (AWARD-CHN2). Diabetes Ther 10(4):1435\u20131452. https:\/\/doi.org\/10.1007\/s13300-019-0646-y","journal-title":"Diabetes Ther"},{"key":"2697_CR59","doi-asserted-by":"publisher","first-page":"6423987","DOI":"10.1155\/2019\/6423987","volume":"2019","author":"H Li","year":"2019","unstructured":"Li H, Xu X, Wang J et al (2019) A Randomized study to compare the effects of once-weekly dulaglutide injection and once-daily glimepiride on glucose fluctuation of type 2 diabetes mellitus patients: a 26-week follow-up. J Diabetes Res 2019:6423987. https:\/\/doi.org\/10.1155\/2019\/6423987","journal-title":"J Diabetes Res"},{"issue":"10192","key":"2697_CR60","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0140-6736(19)31271-1","volume":"394","author":"R Pratley","year":"2019","unstructured":"Pratley R, Amod A, Hoff ST et al (2019) Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet 394(10192):39\u201350. https:\/\/doi.org\/10.1016\/S0140-6736(19)31271-1","journal-title":"Lancet"},{"issue":"8","key":"2697_CR61","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/S2213-8587(19)30184-6","volume":"7","author":"VR Aroda","year":"2019","unstructured":"Aroda VR, Gonz\u00e1lez-Galvez G, Gr\u00f8n R et al (2019) Durability of insulin degludec plus liraglutide versus insulin glargine U100 as initial injectable therapy in type 2 diabetes (DUAL VIII): a multicentre, open-label, phase 3b, randomised controlled trial. Lancet Diabetes Endocrinol 7(8):596\u2013605. https:\/\/doi.org\/10.1016\/S2213-8587(19)30184-6","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"12","key":"2697_CR62","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.2337\/dc19-0883","volume":"42","author":"HW Rodbard","year":"2019","unstructured":"Rodbard HW, Rosenstock J, Canani LH et al (2019) Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: the PIONEER 2 trial. Diabetes Care 42(12):2272\u20132281. https:\/\/doi.org\/10.2337\/dc19-0883","journal-title":"Diabetes Care"},{"issue":"5","key":"2697_CR63","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/S2213-8587(19)30066-X","volume":"7","author":"B Zinman","year":"2019","unstructured":"Zinman B, Bhosekar V, Busch R et al (2019) Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial. Lancet Diabetes Endocrinol 7(5):356\u2013367. https:\/\/doi.org\/10.1016\/S2213-8587(19)30066-X","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"12","key":"2697_CR64","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.2337\/dc19-0898","volume":"42","author":"B Zinman","year":"2019","unstructured":"Zinman B, Aroda VR, Buse JB et al (2019) Efficacy, safety, and tolerability of oral semaglutide versus placebo added to insulin with or without metformin in patients with type 2 diabetes: the PIONEER 8 trial. Diabetes Care 42(12):2262\u20132271. https:\/\/doi.org\/10.2337\/dc19-0898","journal-title":"Diabetes Care"},{"issue":"7","key":"2697_CR65","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/S2213-8587(19)30194-9","volume":"7","author":"TR Pieber","year":"2019","unstructured":"Pieber TR, Bode B, Mertens A et al (2019) Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial. Lancet Diabetes Endocrinol 7(7):528\u2013539. https:\/\/doi.org\/10.1016\/S2213-8587(19)30194-9","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"2697_CR66","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1111\/dom.13682","volume":"21","author":"J Unger","year":"2019","unstructured":"Unger J, Allison DC, Carlton M et al (2019) Trial design and baseline data for LIRA-PRIME: a randomized trial investigating the efficacy of liraglutide in controlling glycaemia in type 2 diabetes in a primary care setting. Diabetes Obes Metab 21(7):1543\u20131550. https:\/\/doi.org\/10.1111\/dom.13682","journal-title":"Diabetes Obes Metab"},{"issue":"15","key":"2697_CR67","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1001\/jama.2019.2942","volume":"321","author":"J Rosenstock","year":"2019","unstructured":"Rosenstock J, Allison D, Birkenfeld AL et al (2019) Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea: the PIONEER 3 randomized clinical trial. JAMA 321(15):1466\u20131480. https:\/\/doi.org\/10.1001\/jama.2019.2942","journal-title":"JAMA"},{"issue":"9","key":"2697_CR68","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1056\/NEJMoa1901118","volume":"381","author":"M Husain","year":"2019","unstructured":"Husain M, Birkenfeld AL, Donsmark M et al (2019) Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 381(9):841\u2013851. https:\/\/doi.org\/10.1056\/NEJMoa1901118","journal-title":"N Engl J Med"},{"issue":"10193","key":"2697_CR69","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR et al (2019) Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 394(10193):121\u2013130. https:\/\/doi.org\/10.1016\/S0140-6736(19)31149-3","journal-title":"Lancet"},{"key":"2697_CR70","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s40842-019-0088-5","volume":"6","author":"JA Davidson","year":"2020","unstructured":"Davidson JA, Stager W, Paranjape S et al (2020) Achieving postprandial glucose control with lixisenatide improves glycemic control in patients with type 2 diabetes on basal insulin: a post-hoc analysis of pooled data. Clin Diabetes Endocrinol 6:2. https:\/\/doi.org\/10.1186\/s40842-019-0088-5","journal-title":"Clin Diabetes Endocrinol"},{"issue":"10","key":"2697_CR71","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.2337\/dc19-1350","volume":"43","author":"SA Jabbour","year":"2020","unstructured":"Jabbour SA, Fr\u00edas JP, Ahmed A et al (2020) Efficacy and safety over 2 years of exenatide plus dapagliflozin in the DURATION-8 study: a multicenter, double-blind, phase 3, randomized controlled trial. Diabetes Care 43(10):2528\u20132536. https:\/\/doi.org\/10.2337\/dc19-1350","journal-title":"Diabetes Care"},{"issue":"2","key":"2697_CR72","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.diabet.2019.101117","volume":"46","author":"MS Capehorn","year":"2020","unstructured":"Capehorn MS, Catarig AM, Furberg JK et al (2020) Efficacy and safety of once-weekly semaglutide 1.0\u00a0mg vs once-daily liraglutide 1.2\u00a0mg as add-on to 1\u20133 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). Diabetes Metab 46(2):100\u2013109. https:\/\/doi.org\/10.1016\/j.diabet.2019.101117","journal-title":"Diabetes Metab"},{"issue":"5","key":"2697_CR73","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.2337\/dc19-1745","volume":"43","author":"WT Garvey","year":"2020","unstructured":"Garvey WT, Birkenfeld AL, Dicker D et al (2020) Efficacy and safety of liraglutide 3.0\u00a0mg in individuals with overweight or obesity and type 2 diabetes treated with basal insulin: The SCALE insulin randomized controlled trial. Diabetes Care 43(5):1085\u20131093. https:\/\/doi.org\/10.2337\/dc19-1745","journal-title":"Diabetes Care"},{"issue":"10278","key":"2697_CR74","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","volume":"397","author":"M Davies","year":"2021","unstructured":"Davies M, F\u00e6rch L, Jeppesen OK et al (2021) Semaglutide 2\u00b74\u00a0mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet 397(10278):971\u2013984. https:\/\/doi.org\/10.1016\/S0140-6736(21)00213-0","journal-title":"Lancet"},{"issue":"2","key":"2697_CR75","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1111\/dom.14232","volume":"23","author":"L Ji","year":"2021","unstructured":"Ji L, Dong X, Li Y et al (2021) Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as add-on to metformin in patients with type 2 diabetes in SUSTAIN China: a 30-week, double-blind, phase 3a, randomized trial. Diabetes Obes Metab 23(2):404\u2013414. https:\/\/doi.org\/10.1111\/dom.14232","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"2697_CR76","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJMoa2108269","volume":"385","author":"HC Gerstein","year":"2021","unstructured":"Gerstein HC, Sattar N, Rosenstock J et al (2021) Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. N Engl J Med 385(10):896\u2013907. https:\/\/doi.org\/10.1056\/NEJMoa2108269","journal-title":"N Engl J Med"},{"issue":"6","key":"2697_CR77","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.2337\/dc20-2151","volume":"44","author":"R Nahra","year":"2021","unstructured":"Nahra R, Wang T, Gadde KM et al (2021) Effects of cotadutide on metabolic and hepatic parameters in adults with overweight or obesity and type 2 diabetes: a 54-week randomized phase 2b study. Diabetes Care 44(6):1433\u20131442. https:\/\/doi.org\/10.2337\/dc20-2151","journal-title":"Diabetes Care"},{"issue":"9","key":"2697_CR78","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1111\/dom.14765","volume":"24","author":"M Kellerer","year":"2022","unstructured":"Kellerer M, Kaltoft MS, Lawson J et al (2022) Effect of once-weekly semaglutide versus thrice-daily insulin aspart, both as add-on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes (SUSTAIN 11): a randomized, open-label, multinational, phase 3b trial. Diabetes Obes Metab 24(9):1788\u20131799. https:\/\/doi.org\/10.1111\/dom.14765","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"2697_CR79","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.2337\/dc21-2656","volume":"45","author":"JP Frias","year":"2022","unstructured":"Frias JP, Choi J, Rosenstock J et al (2022) Efficacy and safety of once-weekly efpeglenatide monotherapy versus placebo in type 2 diabetes: the AMPLITUDE-M randomized controlled trial. Diabetes Care 45(7):1592\u20131600. https:\/\/doi.org\/10.2337\/dc21-2656","journal-title":"DiabetesCare"},{"issue":"12","key":"2697_CR80","doi-asserted-by":"publisher","first-page":"3690","DOI":"10.1111\/dom.15263","volume":"25","author":"W Wang","year":"2023","unstructured":"Wang W, Yan X, Cheng Z et al (2023) Efficacy and safety of adding once-weekly dulaglutide to basal insulin for inadequately controlled type 2 diabetes in Chinese patients (AWARD-CHN3): a randomized, double-blind, placebo-controlled, phase III trial. Diabetes Obes Metab 25(12):3690\u20133699. https:\/\/doi.org\/10.1111\/dom.15263","journal-title":"Diabetes Obes Metab"},{"issue":"10400","key":"2697_CR81","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/S0140-6736(23)01302-8","volume":"402","author":"JP Frias","year":"2023","unstructured":"Frias JP, Hsia S, Eyde S et al (2023) Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study. Lancet 402(10400):472\u2013483. https:\/\/doi.org\/10.1016\/S0140-6736(23)01302-8","journal-title":"Lancet"},{"issue":"3","key":"2697_CR82","doi-asserted-by":"publisher","first-page":"e003206","DOI":"10.1136\/bmjdrc-2022-003206","volume":"11","author":"JB Buse","year":"2023","unstructured":"Buse JB, Nordahl Christensen H, Harty BJ et al (2023) Study design and baseline profile for adults with type 2 diabetes in the once-weekly subcutaneous SEmaglutide randomized PRAgmatic (SEPRA) trial. BMJ Open Diabetes Res Care 11(3):e003206. https:\/\/doi.org\/10.1136\/bmjdrc-2022-003206","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"9","key":"2697_CR83","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1007\/s00125-024-06142-3","volume":"67","author":"W Wang","year":"2024","unstructured":"Wang W, Bain SC, Bian F et al (2024) Efficacy and safety of oral semaglutide monotherapy vs placebo in a predominantly Chinese population with type 2 diabetes (PIONEER 11): a double-blind, Phase IIIa, randomised trial. Diabetologia 67(9):1783\u20131799. https:\/\/doi.org\/10.1007\/s00125-024-06142-3","journal-title":"Diabetologia"},{"issue":"2","key":"2697_CR84","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.joca.2021.04.020","volume":"30","author":"KD Allen","year":"2022","unstructured":"Allen KD, Thoma LM, Golightly YM (2022) Epidemiology of osteoarthritis. Osteoarthritis Cartilage 30(2):184\u2013195. https:\/\/doi.org\/10.1016\/j.joca.2021.04.020","journal-title":"Osteoarthritis Cartilage"},{"issue":"9","key":"2697_CR85","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1136\/ard-2023-223845","volume":"82","author":"H Zhu","year":"2023","unstructured":"Zhu H, Zhou L, Wang Q et al (2023) Glucagon-like peptide-1 receptor agonists as a disease-modifying therapy for knee osteoarthritis mediated by weight loss: findings from the Shanghai Osteoarthritis Cohort. Ann Rheum Dis 82(9):1218\u20131226. https:\/\/doi.org\/10.1136\/ard-2023-223845","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"2697_CR86","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1111\/os.13809","volume":"15","author":"X Du","year":"2023","unstructured":"Du X, Liu ZY, Tao XX et al (2023)Research progress on the pathogenesis of knee osteoarthritis. Orthop Surg 15(9):2213\u20132224. https:\/\/doi.org\/10.1111\/os.13809","journal-title":"Orthop Surg"},{"issue":"6","key":"2697_CR87","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1007\/s12325-022-02153-x","volume":"39","author":"M Jensterle","year":"2022","unstructured":"Jensterle M, Rizzo M, Haluz\u00edk M et al (2022) Efficacy of GLP-1 RA approved for weight management in patients with or without diabetes: a narrative review. Adv Ther 39(6):2452\u20132467. https:\/\/doi.org\/10.1007\/s12325-022-02153-x","journal-title":"Adv Ther"},{"issue":"12","key":"2697_CR88","doi-asserted-by":"publisher","first-page":"e68","DOI":"10.1016\/j.arth.2024.08.035","volume":"39","author":"K Ng","year":"2024","unstructured":"Ng K, Ellis R, Mobasheri A et al (2024) Why did the five-year incidence of progression to osteoarthritis and total joint arthroplasty in patients prescribed glucagon-like peptide 1 (GLP-1) receptor agonists differ from previous randomized controlled study? J Arthroplasty 39(12):e68\u2013e69. https:\/\/doi.org\/10.1016\/j.arth.2024.08.035","journal-title":"J Arthroplasty"},{"issue":"12","key":"2697_CR89","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.2337\/dci18-0033","volume":"41","author":"MJ Davies","year":"2018","unstructured":"Davies MJ, D\u2019Alessio DA, Fradkin J et al (2018) Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 41(12):2669\u20132701. https:\/\/doi.org\/10.2337\/dci18-0033","journal-title":"Diabetes Care"},{"issue":"2","key":"2697_CR90","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/s41419-017-0217-y","volume":"9","author":"J Chen","year":"2018","unstructured":"Chen J, Xie JJ, Shi KS et al (2018) Glucagon-like peptide-1 receptor regulates endoplasmic reticulum stress-induced apoptosis and the associated inflammatory response in chondrocytes and the progression of osteoarthritis in rat. Cell Death Dis 9(2):212. https:\/\/doi.org\/10.1038\/s41419-017-0217-y","journal-title":"Cell Death Dis"},{"issue":"6","key":"2697_CR91","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1007\/s13300-019-00706-y","volume":"10","author":"S Nuhoho","year":"2019","unstructured":"Nuhoho S, Gupta J, Hansen BB et al (2019) Orally administered semaglutide versus GLP-1 RAs in patients with type 2 diabetes previously receiving 1\u20132 oral antidiabetics: systematic review and network meta-analysis. Diabetes Ther 10(6):2183\u20132199. https:\/\/doi.org\/10.1007\/s13300-019-00706-y","journal-title":"Diabetes Ther"},{"key":"2697_CR92","doi-asserted-by":"publisher","first-page":"645617","DOI":"10.3389\/fendo.2021.645617","volume":"12","author":"JJ Meier","year":"2021","unstructured":"Meier JJ (2021) Efficacy of semaglutide in a subcutaneous and an oral formulation. Front Endocrinol (Lausanne) 12:645617. https:\/\/doi.org\/10.3389\/fendo.2021.645617","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"2697_CR93","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1186\/s12891-024-07640-6","volume":"25","author":"X Zhang","year":"2024","unstructured":"Zhang X, Jiang J, Xu J et al (2024) Liraglutide, a glucagon-like peptide-1 receptor agonist, ameliorates inflammation and apoptosis via inhibition of receptor for advanced glycation end products signaling in AGEs induced chondrocytes. BMC Musculoskelet Disord 25(1):601. https:\/\/doi.org\/10.1186\/s12891-024-07640-6","journal-title":"BMC Musculoskelet Disord"},{"issue":"1","key":"2697_CR94","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1038\/s41598-022-05323-7","volume":"12","author":"C Meurot","year":"2022","unstructured":"Meurot C, Martin C, Sudre L et al (2022) Liraglutide, a glucagon-like peptide 1 receptor agonist, exerts analgesic, anti-inflammatory and anti-degradative actions in osteoarthritis. Sci Rep 12(1):1567. https:\/\/doi.org\/10.1038\/s41598-022-05323-7","journal-title":"Sci Rep"},{"issue":"8","key":"2697_CR95","first-page":"4800","volume":"11","author":"J Mei","year":"2019","unstructured":"Mei J, Sun J, Wu J, Zheng X (2019) Liraglutide suppresses TNF-\u03b1-induced degradation of extracellular matrix in human chondrocytes: a therapeutic implication in osteoarthritis. Am J Transl Res 11(8):4800\u20134808","journal-title":"Am J Transl Res"},{"issue":"4","key":"2697_CR96","first-page":"2081","volume":"11","author":"C Tong","year":"2019","unstructured":"Tong C, Liang H, Liu X et al (2019) The protective effects of exenatide against AGEs-induced articular matrix degradation in human primary chondrocytes. Am J Transl Res 11(4):2081\u20132089","journal-title":"Am J Transl Res"},{"key":"2697_CR97","doi-asserted-by":"publisher","first-page":"108968","DOI":"10.1016\/j.cbi.2020.108968","volume":"322","author":"H Li","year":"2020","unstructured":"Li H, Chen J, Li B, Fang X (2020) The protective effects of dulaglutide against advanced glycation end products (AGEs)-induced degradation of type \u2161 collagen and aggrecan in human SW1353 chondrocytes. Chem Biol Interact 322:108968. https:\/\/doi.org\/10.1016\/j.cbi.2020.108968","journal-title":"Chem Biol Interact"},{"issue":"1","key":"2697_CR98","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1080\/21691401.2019.1593996","volume":"47","author":"X Li","year":"2019","unstructured":"Li X, Jia F, Zhu Z et al (2019) Lixisenatide attenuates advanced glycation end products (AGEs)-induced degradation of extracellular matrix in human primary chondrocytes. Artif Cells Nanomed Biotechnol 47(1):1256\u20131264. https:\/\/doi.org\/10.1080\/21691401.2019.1593996","journal-title":"Artif Cells Nanomed Biotechnol"}],"container-title":["Acta Diabetologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-026-02697-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00592-026-02697-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-026-02697-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T11:24:53Z","timestamp":1784805893000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00592-026-02697-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,8]]},"references-count":98,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["2697"],"URL":"https:\/\/doi.org\/10.1007\/s00592-026-02697-2","relation":{},"ISSN":["1432-5233"],"issn-type":[{"value":"1432-5233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,8]]},"assertion":[{"value":"14 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have reviewed and approved the manuscript for submission.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}